Posted by Michael Wonder on 28 Feb 2026
Opus Genetics announces FDA acceptance of supplemental new drug application for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia
25 February 2026 - Opus Genetics today announced that the US FDA has accepted for review the supplemental new drug application for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia.
The FDA has assigned a PDUFA goal date of 17 October 2026.
